C. Tournigand
About
C. Tournigand is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology.
According to data from OpenAlex, C. Tournigand has authored 35 papers receiving a total of 607 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 7 papers in Hepatology. Recurrent topics in C. Tournigand's work include Colorectal Cancer Treatments and Studies (26 papers), Cancer Treatment and Pharmacology (21 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). C. Tournigand is often cited by papers focused on Colorectal Cancer Treatments and Studies (26 papers), Cancer Treatment and Pharmacology (21 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). C. Tournigand collaborates with scholars based in France, Spain and United States. C. Tournigand's co-authors include Aimery de Gramont, Thierry André, Christophe Louvet, M Krulik, Richard M. Goldberg, Daniel J. Sargent, Leonard B. Saltz, Philippe Rougier, Michel Seymour and Jean‐Yves Douillard and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.
In The Last Decade
C. Tournigand
32 papers receiving 594 citations
Peers
C. Tournigand
Laurent Bastit France
Louise Nott Australia
Alfonso Yubero Spain
Ignazio Carreca Italy
Andrea Corkhill United Kingdom
Alexandre A. Jácome Brazil
M. Borner Switzerland
Nobutomo Miyanari Japan
M. Lorenz Germany
J Lokich United States
Citations per year, relative to C. Tournigand C. Tournigand (= 1×)
peers
Laurent Bastit
Countries citing papers authored by C. Tournigand
Since
Specialization
Citations
This map shows the geographic impact of C. Tournigand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Tournigand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Tournigand more than expected).
Fields of papers citing papers by C. Tournigand
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by C. Tournigand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Tournigand. The network helps show where C. Tournigand may publish in the future.
Co-authorship network of co-authors of C. Tournigand
This figure shows the co-authorship network connecting the top 25 collaborators of C. Tournigand. A scholar is included among the top collaborators of C. Tournigand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Tournigand. C. Tournigand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Duong, T.A., et al.. (2025). Concordance between patient-reported outcomes and CTCAE clinician-reported toxicities during outpatient chemotherapy courses: a retrospective cohort study in routine care. PubMed. 8. 100127–100127.
2.
Meylan, Maxime, Maria João Moreira, Antoine Bougoüin, et al.. (2022). 1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial. Annals of Oncology. 33. S1207–S1207.
3.
Beinse, Guillaume, Lauriane Ségaux, C. Tournigand, et al.. (2017). Potential drug interactions in older patients with cancer: Updated data from the ELCAPA cohort survey. Annals of Oncology. 28. v557–v558.
4.
Canouï‐Poitrine, Florence, Astrid Lièvre, Iris Baumgärtner, et al.. (2017). Inclusion of older patients with colorectal cancer in clinical trials: the SAGE prospective multicenter cohort study. Annals of Oncology. 28. v512–v513.
5.
Watson, Sarah, Pierre Validire, Pascale Cervera, et al.. (2013). Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study. Annals of Oncology. 24(12). 3035–3039.
6.
André, Thierry, Hélène Blons, May Mabro, et al.. (2012). Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Annals of Oncology. 24(2). 412–419.
7.
Rousseau, Benoı̂t, Pierre Loulergue, Olivier Mir, et al.. (2011). Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study. Annals of Oncology. 23(2). 450–457.
8.
Ansquer, Y., Piétro Santulli, Chrystelle Colas, et al.. (2010). Néoplasies lobulaires intra-épithéliales : hyperplasie lobulaire atypique et cancer lobulaire in situ. Journal de gynécologie, obstétrique et biologie de la reproduction. Supplément. 39(2). 91–101.
9.
Chibaudel, Benoist, C. Tournigand, Franck Bonnetain, et al.. (2010). Handy prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer.. Journal of Clinical Oncology. 28(15_suppl). 3577–3577.
10.
Ramanathan, R. K., Mace L. Rothenberg, Aimery de Gramont, et al.. (2009). Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies. Annals of Oncology. 21(4). 754–758.
11.
Chibaudel, Benoist, C. Tournigand, Pascal Artru, et al.. (2009). FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study. Annals of Oncology. 20(8). 1383–1386.
12.
Sargent, Daniel J., Claus Henning Köhne, Hanna K. Sanoff, et al.. (2009). Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology. 27(12). 1948–1955.
13.
Tournigand, C., Benoît Samson, Werner Scheithauer, et al.. (2009). mFOLFOX-bevacizumab or XELOX-bevacizumab then bevacizumab (B) alone or with erlotinib (E) in first-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety analysis of DREAM study. Journal of Clinical Oncology. 27(15_suppl). 4077–4077.
14.
Goldberg, Richard M., C.-H. Köhne, Michel Seymour, et al.. (2007). A pooled safety and efficacy analysis examining the effect of performance status (PS) on outcomes in nine first-line treatment (rx) trials (cts) of 6,286 patients (pts) with metastatic colorectal cancer (MCRC). Journal of Clinical Oncology. 25(18_suppl). 4011–4011.
15.
Tournigand, C., et al.. (2006). Targeted Agents for Adjuvant Therapy of Colon Cancer. Seminars in Oncology. 33(6 Suppl 11). 42–45.
16.
Gramont, Aimery de, Hans‐Joachim Schmoll, Andrés Cervantes, & C. Tournigand. (2003). The evolving role of oxaliplatin in the management of colorectal cancer. Colorectal Disease. 5(s3). 10–19.
17.
Gramont, Aimery de, Christophe Louvet, Thierry André, C. Tournigand, & M Krulik. (1998). A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a Regimen. European Journal of Cancer. 34(5). 619–626.
18.
Gramont, Aimery de, C. Tournigand, Christophe Louvet, et al.. (1997). Oxaliplatin, leucovorin and fluorouracil in pretreated patients with advanced colorectal cancer.. La Revue de Médecine Interne. 10(18). 769–775.
19.
Gramont, Aimery de, C. Tournigand, Christophe Louvet, et al.. (1997). Oxaliplatine, acide folinique et 5-fluorouracile (folfox) en seconde ligne thérapeutique du cancer colorectal métastasé. La Revue de Médecine Interne. 18(10). 769–775.
20.
Gramont, Aimery de, Christophe Louvet, Thierry André, et al.. (1997). La modulation du 5-fluorouracile par l'acide folinique dans les cancers colorectaux avancés. La Revue de Médecine Interne. 18. 372s–378s.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Laurent Bastit Breakdown of academic impact, for papers by Louise Nott Breakdown of academic impact, for papers by Alfonso Yubero Breakdown of academic impact, for papers by Ignazio Carreca Breakdown of academic impact, for papers by Andrea Corkhill Breakdown of academic impact, for papers by Alexandre A. Jácome Breakdown of academic impact, for papers by M. Borner Breakdown of academic impact, for papers by Nobutomo Miyanari Breakdown of academic impact, for papers by M. Lorenz Breakdown of academic impact, for papers by J Lokich